We then investigated the association of CCL2 concentration in prostate cancer patient serum with time-to-event outcomes by performing univariable and multivariable analysis with 10-year endpoint data from the TROG 03.04 RADAR trial (Table 6). Here, CCL2 is linked to prostate cancer.